Risk factors for liver-related mortality of patients with hepatitis C virus after sustained virologic response to direct-acting antiviral agents.
diabetes mellitus
direct‐acting antiviral agents
hepatitis C virus
survival
sustained virologic response
Journal
JGH open : an open access journal of gastroenterology and hepatology
ISSN: 2397-9070
Titre abrégé: JGH Open
Pays: Australia
ID NLM: 101730833
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
received:
03
03
2022
revised:
01
07
2022
accepted:
27
07
2022
entrez:
20
10
2022
pubmed:
21
10
2022
medline:
21
10
2022
Statut:
epublish
Résumé
The aim of this study was to identify the factors associated with liver-related and non-liver-related mortality of patients with hepatitis C virus (HCV) after sustained virologic response (SVR) to direct-acting antiviral agents (DAAs). We conducted a retrospective, single-center cohort study of HCV patients cured by DAAs. A total of 330 patients with SVR to DAAs were eligible. The median follow-up period was 3.38 years (inter-quartile range: 2.03-4.58). The cumulative liver-related or non-liver-related mortality rates at 1, 3, and 5 years were 0.00 or 1.29%, 2.87 or 3.60%, and 5.10 or 9.46, respectively. Among the liver-related deaths, 9 of the 10 were from liver cancer. Among the non-liver-related deaths, the most common cause was malignancy. Through multivariate analysis using the Cox proportional hazard model, diabetes mellitus (DM, hazard ratio 13.1, 95% confidence interval 2.81-61.3) and a history of hepatocellular carcinoma (HCC, 12.8, 2.76-59.2), independently predicted liver-related death. No variables were associated with non-liver-related death. Our findings suggest that DM and a history of HCC are risk factors for liver-related mortality of HCV patients cured by DAAs. These results indicate that early management of HCV and HCC surveillance of diabetic patients after SVR are important to increase the chance of survival. Further studies are needed to confirm the association of DM and HCC history with survival.
Sections du résumé
Background and Aim
UNASSIGNED
The aim of this study was to identify the factors associated with liver-related and non-liver-related mortality of patients with hepatitis C virus (HCV) after sustained virologic response (SVR) to direct-acting antiviral agents (DAAs).
Methods
UNASSIGNED
We conducted a retrospective, single-center cohort study of HCV patients cured by DAAs.
Results
UNASSIGNED
A total of 330 patients with SVR to DAAs were eligible. The median follow-up period was 3.38 years (inter-quartile range: 2.03-4.58). The cumulative liver-related or non-liver-related mortality rates at 1, 3, and 5 years were 0.00 or 1.29%, 2.87 or 3.60%, and 5.10 or 9.46, respectively. Among the liver-related deaths, 9 of the 10 were from liver cancer. Among the non-liver-related deaths, the most common cause was malignancy. Through multivariate analysis using the Cox proportional hazard model, diabetes mellitus (DM, hazard ratio 13.1, 95% confidence interval 2.81-61.3) and a history of hepatocellular carcinoma (HCC, 12.8, 2.76-59.2), independently predicted liver-related death. No variables were associated with non-liver-related death.
Conclusion
UNASSIGNED
Our findings suggest that DM and a history of HCC are risk factors for liver-related mortality of HCV patients cured by DAAs. These results indicate that early management of HCV and HCC surveillance of diabetic patients after SVR are important to increase the chance of survival. Further studies are needed to confirm the association of DM and HCC history with survival.
Identifiants
pubmed: 36262540
doi: 10.1002/jgh3.12805
pii: JGH312805
pmc: PMC9575322
doi:
Types de publication
Journal Article
Langues
eng
Pagination
685-691Informations de copyright
© 2022 The Authors. JGH Open published by Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.
Références
J Gastroenterol Hepatol. 2017 Jul;32(7):1355-1362
pubmed: 27930829
Diabetol Int. 2020 Jul 24;11(3):165-223
pubmed: 32802702
J Gastroenterol. 2020 Oct;55(10):990-999
pubmed: 32770465
Hepatology. 2016 Nov;64(5):1442-1450
pubmed: 27015107
J Viral Hepat. 2021 Aug;28(8):1190-1199
pubmed: 33896097
Chin Med J (Engl). 2015 Jun 5;128(11):1543-8
pubmed: 26021514
Sci Rep. 2013;3:1065
pubmed: 23323209
Proteomics Clin Appl. 2013 Oct;7(9-10):642-7
pubmed: 23640794
Hepatol Int. 2019 Nov;13(6):649-661
pubmed: 31541423
J Hepatol. 2021 Nov;75(5):1049-1057
pubmed: 34097994
Clin Gastroenterol Hepatol. 2019 May;17(6):1183-1191.e7
pubmed: 30613002
J Hepatol. 2022 Feb;76(2):302-310
pubmed: 34592366
Lancet. 2019 Apr 6;393(10179):1453-1464
pubmed: 30765123
Lancet Gastroenterol Hepatol. 2017 Mar;2(3):161-176
pubmed: 28404132
World J Gastroenterol. 2017 Mar 7;23(9):1697-1711
pubmed: 28321170
Hepatology. 2020 Feb;71(2):686-721
pubmed: 31816111
Hepatology. 2019 Feb;69(2):487-497
pubmed: 28749564
Hepatology. 2018 Sep;68(3):827-838
pubmed: 29377196
Hepatology. 2007 Jul;46(1):32-6
pubmed: 17567829
N Engl J Med. 2021 Mar 18;384(11):1038-1052
pubmed: 33730456
Medicine (Baltimore). 2017 Mar;96(13):e6508
pubmed: 28353605
Aliment Pharmacol Ther. 2017 Oct;46(8):731-740
pubmed: 28833342
Hepatol Res. 2020 Jul;50(7):791-816
pubmed: 32343477
Gut. 2005 Apr;54(4):533-9
pubmed: 15753540
J Natl Cancer Inst. 1999 Mar 17;91(6):542-7
pubmed: 10088625
Hepatol Res. 2019 Oct;49(10):1109-1113
pubmed: 31336394
Cancer Causes Control. 1995 Mar;6(2):164-79
pubmed: 7749056
Front Med (Lausanne). 2021 Oct 18;8:744512
pubmed: 34733865